Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
02:24am, Wednesday, 30'th Jun 2021
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
07:00am, Thursday, 27'th May 2021
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializati
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
07:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat
Why Crispr, KalVista And Syndax Are Moving Today
09:18am, Tuesday, 20'th Apr 2021
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
08:18am, Tuesday, 20'th Apr 2021
Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
06:30am, Tuesday, 20'th Apr 2021
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue Estimates
08:20am, Thursday, 11'th Mar 2021
KalVista Pharmaceuticals, Inc. (KALV) delivered earnings and revenue surprises of 6.67% and -100.00%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
06:30am, Thursday, 11'th Mar 2021
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?
01:38pm, Tuesday, 02'nd Mar 2021
KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
07:30am, Thursday, 18'th Feb 2021
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development
07:18am, Thursday, 11'th Feb 2021
KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offere
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
09:52pm, Wednesday, 10'th Feb 2021
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 sha
Can KalVista Pharmaceuticals Stock Fly Higher?
07:25am, Wednesday, 10'th Feb 2021
Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?
Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today
09:46pm, Tuesday, 09'th Feb 2021
Analysts say the biotech's investors could be in store for even more gains.
